Introduction
Although some 30 years have elapsed since 5-HT (serotonin) was first identified in the central nervous system (CNS), the precise role of the neurotransmitter in the control of behavior is still unclear. However, progress in serotonin research is now accelerating at a fast pace following the discovery of multiple subtypes of 5-HT receptor and the availability of novel drugs acting at these sites with appreciable degrees of affinity and selectivity. As with any rapidly expanding field, problems of nomenclature and classification cause enormous controversy and confusion. A working party has recently published guidelines for the subdivision of 5-HT receptors into three major populations: 5-HT,, 5-HT~ and 5-HT3 (Bradley et al, 1986) , combining the dichotomy of M (5-HT3) and D (5-HT2) originally proposed by Gaddum and Picarelli in 1957 with the 5-HT1 ¡ and 5-HT2 classification of Peroutka and Snyder (1979) . While there is evidence for heterogeneity within the 5-HT, subdivision, it was felt to be strong enough to warrant only the vague and conservative designation of the term '5-HT1-like' and insufficient to allow a rigorous dissection into 5-HTIA, 5-HTIB ... 5-HT,~. Strictly speaking, this is still valid since selective antagonists and, in some cases, selective agonists of subtypes of the 5-HT, receptor have yet to be identified. Nevertheless, evidence in favour of the existence of at least three 5-HT, subtypes, lA, 1B and 1C, is now very strong and attempts to further subdivide (not only the 5-HT, receptor) continue. It is the aim of this article to assemble the proposals that have been made so far.
5-HT and subtypes
The 5-HT recognition site was originally ident-ified by its high affinity, vis-à-vis the 5-HT2 receptor, for [3H]5-HT in radioligand binding assays (Peroutka and Snyder, 1979) . Subdivision into two subtypes, designated 5-HTIA and 5-HTIB, was made firstly on the basis of the high and low affinity components of the displacement of [3H] 5-HT by spiperone (Deshmukh et al., 1982) .
Confirmation of the importance of the 5-HT1A recognition site was obtained with the discovery that the 5-HT receptor agonist, 8-hydroxy-2-(din-propylamino)-tetralin (8-OH-DPAT), has very high affinity for the spiperone-sensitive 5-HTIA site that was several orders of magnitude greater than for 5-HT1B or 5-HT2 sites (Middlemiss and Fozard, 1983) . Since that time a number of other selective 5-HTIA ligands have been identified, including dipropyl-5-carboxyamidotryptamine (Hagenbach et al., 1986) , MDL 72832 (Fozard et al., 1987) , MDL 73005 (Hibert et al., 1988) and the novel anxiolytics, buspirone and ipsapirone (Gozlan et al., 1983; Peroutka, 1985) . A number of responses to 8-OH-DPAT, both in vitro and in vivo, are also induced by these compounds and show a pharmacological profile consistent with activation of the 5-HTIA recognition site: they are blocked by (-)-pindolol, spiperone and methiothepin, which have in common high affinity for 5-HTlA sites, but not blocked by &oelig;-or P-adrenoceptor, 5-HT2 or dopamine receptor antagonists devoid of such effects (Dourish, Ahlenius and Hutson, 1987) .
While a selective 5-HTIA antagonist has not been identified, it should be noted that MDL 72832, MDL 73005, buspirone and ipsapirone are partial agonists with antagonist properties in some preparations (Fozard et al., 1987; De Vivo and Maayani, 1986; Bockaert et al., 1987 , Hibert et al., 1988 Mir et al., 1988) . The evidence strongly indicates that the 5-HT1A recognition site is a functional receptor.
While the 5-HTIB recognition site was orig- Wolfe and Frazer, 1984) , but their selectivity is questionable: RU 24969 has equally high affinity for the 5-HTIA recognition site (Tricklebank, Middlemiss and Neill, 1986 ) while TFMPP and mCPP may act at 5-HT1c sites (see below). Unfortunately, research in this area has now lost some impetus with respect to drug discovery following the failure to identify the 5-HTIB binding site in the human brain (Hoyer et al., 1986) .
Evidence for a third '5-HT1-like' receptor, 5-HT1c, has come from studies not of the CNS, but of the epithelial cells of the choroid plexus.
Radioligands are [3H] 5-HT, [125IJ LSD and [3H] mesulergine. None are in any way selective but the displacement of these ligands by 5-HT agonists and antagonists in the tissue is clearly different from their displacement at 5-HT1A, 5-HTIB, or 5-HT2 sites: metergoline, mesulergine, mianserin, methysergide and cyproheptadine have high affinity; spiperone, ketanserin, (-)pindolol, 8-OH-DPAT and RU 24969 displace only at concentrations much higher than at their respective 'preferred' sites of action (Pazos, Hoyer and Palacios, 1984; Yagaloff and Hartig, 1985; Engel et al., 1986) . The binding site has the characteristics of a functional receptor since it is linked to the phosphatidylinositol second messenger system (Conn et al., 1986), where 5-HT, MK-212, TFMPP and mCPP also act as agonists (Conn and Sanders-Bush, 1987). Unlike the 5-HTlB recognition site, 5-HT1C sites have been demonstrated in human brain, notably substantia nigra, globus pallidus and ventromedial hypothalamus (Hoyer et al., 1986, Pazos, Probst and Palacios, 1987) . There is some evidence that hypolocomotion induced by mCPP and TFMPP may reflect activation of the 5-HTic site (Kennett and Curzon, 1988) . Progress in cloning the 5-HT1C gene has been made (Lubbert et al., 1987) . From a classical pharmacological approach, a unique '5-HTi-like' receptor has been identified in the dog saphenous vein and in dog and primate basilar artery (Bradley et al., 1986) . Two compounds, GR 43175 and AH 25086, mimic the contractile effects of 5-HT and 5-carboxamidotryptamine (5-CT); methiothepin is a potent antagonist (Humphrey et al., ,1987 (Humphrey et al., , , 1988 . Unlike both 5-HT and 5-CT, GR 43175 and AH 25086 are unable to induce smooth muscle (for example, porcine vena cava) relaxation. Little is known of the radioligand binding profile of these compounds, but the response in the dog saphenous vein is resistant to blockade by cyanopindolol, ketanserin, cyproheptadine and the 5-hot 3 receptor antagonist, MDL 72222 (Humphrey et al., 1987a, b) . The behavioural effects of GR 43175 and AH 25086 are currently unknown. It will also be of interest to determine their properties on the guinea-pig 5-HT autoreceptor.
Using a combination of electrophysiology and agonist binding data, an enteric neuronal '5-HT 1like' receptor has been identified for which 6-hyroxyindalpine and 5-hydroxytryptophan dipeptide are agonist and antagonists respectively (Branchek, Mawe and Gershon, 1987) . The proposed nomenclature for this site is 5-HT,p. As for other putative subtypes of the 5-HTt 1 receptor, only the availability of more potent and specific ligands will confirm their functional relevance.
The existence of the 5-HTID recognition site is based on studies of the bovine caudate nucleus using [3H] 5-HT as the radioligand in the presence of high concentrations of 8-OH-DPAT and mesulergine (Heuring and Peroutka, 1987). RU 24969 and (-)-pindolol are approximately two orders of magnitude less potent than at 5-HT1B sites. 5-CT is as potent as 5-HT. A similar recognition site has been reported to be present in porcine and human brain (Hoyer, Waeber and Palacios, 1987) .
The pharmacological profile of the 5-HTID site is analogous to that seen with the 5-HT-induced inhibition of noradrenaline release in the i5olated perfused rat kidney (Charlton, Bond and Clarke, 1986) . Inconsistent with this hypothesis, however, is the inactivity of rawolscine in the kidney preparation (Clarke, Bond and Charlton, 1987) .
There are some similarities between the 5-HTID site and the terminal autoreceptor of the guinea-pig cortex. Thus, in the guinea-pig, the pA2 of methiothepin against 5-HT-induced inhibition of k+-stimulated [3H] 5-HT release is almost two orders of magnitude greater than in rat cortex where the response has been linked to the 5-HTIB subtype (Middlemiss and Bremer, 1987) . For cyanopinolol the potencies are reversed; cyanopindol is two orders of magnitude more potent in the rat than in the guinea-pig. The inactivities of 8-OH-DPAT, mesulergine and ICS 205-930 suggest that the guinea-pig 5-HT autoreceptor is distinct from the 5-HTIA, 5-HT,c, 5-HT2 and 5-HT3 subtypes. It remains to be seen whether compounds that have high affinity for the 5-HTlD recognition site (for example, metergoline, methysergide and yohimbine) are also potent antagonists of the guineapig autoreceptor.
5-HT2 Receptors
The existence and functional relevance of the 5-HTZ receptor in both the periphery and the CNS, has now been confirmed. Antagonists with high affinity and selectivity vis-a-vis other 5-HT recognition sites include ketanserin, ritanserin and ICI 169369. [3H] Ketanserin (Leysen et al., 1982) and [3H] dimethoxyphenyl-4-bromo-2aminopropane (Titeler, Lyon and Glennon, 1988; Titeler et al., 1985) are antagonist and agonist ligands respectively. Those interested in defining the behavioural relevance of the 5-HT2 2 receptor now have excellent tools with which to work. Indeed, recent studies strongly indicate an important role for 5-HT2 2 receptors in hallucinogenic drug action (see, for example, McKenna and Saavedra, 1987 ; Titeler, Lyon and Glennon, 1988), while in the clinic there is evidence that 5-HT~ receptor antagonists have both hypnotic and anxiolytic activity (Mills and Glennard, Idzikowski, 1986; Arriaga et al., 1984).
5-HT3 Receptors
Highly potent and selective antagonists at 5-HT3 receptors include MDL 72222, ICS 205-930, BRL 43694 and GR 38032F. An agonist of reasonable potency and selectivity is 2-methyl-5-HT (Rich- , 1985) . First demonstrated to be present on sensory nerve afferents, there is now evidence of behavioural and neurochemical effects of these compounds, indicating the presence of 5-HT3 receptors in the CNS (Hagan et al., 1987; Costall, Naylor and Onaivi, 1987) . Indeed, the binding in brain of a tritium-labelled analogue of GR 38032F, ['H] GR 65630, shows the pharmacological characteristics expected of the labelling of a 5-HT3 recognition site (Kilpatrick, Jones and Tyers, 1987).
Analogues of ICS 205-930 show markedly different potencies in antagonizing the action of 5-HT, or 2-methyl-5-HT, in the heart, vagus and gastrointestinal tract, suggesting the existence of three subtypes of 5-HT3 receptor (Richardson et al., 1985) . This exciting proposition raises the possibility of the presence of subtypes in the CNS, each holding the potential for distinct and varied behavioural roles.
Conclusions
The subdivision of the 5-HT receptor, though in a complex and confusing phase, has already yielded much information on the significance of 5-HT in normal and pathological states. While some may loose patience and interest with this apparent plethora of recognition sites (table 1) , hopefully others will be sufficiently stimulated by the progress made so far to contribute further to our understanding of this area of pharmacology. 
